title: The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.
abstract: BACKGROUND
  We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA).
  
  
  METHODS
  In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate (MTX)(n = 60) or placebo + MTX (n = 62) at weeks 0, 2, and 6. At week 14, patients receiving placebo + MTX crossed over to infliximab 6 mg/kg + MTX; patients receiving infliximab 3 mg/kg + MTX continued treatment through week 44. Sera and plasma from eligible patients receiving infliximab 3 mg/kg + MTX (n = 34) and receiving placebo→infliximab 6 mg/kg +MTX (n = 38) were collected at weeks 0, 2, 14, 16, 28, and 52 and analyzed for inflammatory markers (IL-6, IL-12p40, ICAM-1, MMP-3, VEGF, TNF-α, and CRP).
  
  
  RESULTS
  At week 2, decreases from baseline in IL-6, ICAM-1, MMP-3, TNF-α, and CRP were greater with infliximab versus placebo treatment, and with the exception of CRP, these differences were generally maintained through week 14. The decreases from baseline to week 52 in IL-6, ICAM-1, VEGF, MMP-3, and CRP and increases in IL-12p40 levels were larger in patients receiving placebo→infliximab 6 mg/kg +MTX versus infliximab 3 mg/kg + MTX treatment. Patients receiving infliximab 3 mg/kg+MTX who achieved an American College of Rheumatology Pediatric 30 (ACR-Pedi-30) response had significantly larger decreases from baseline in ICAM-1 (p = 0.0105) and MMP-3 (p = 0.0253) at week 2 and in ICAM-1 (p = 0.0304), MMP-3 (p = 0.0091), and CRP (p = 0.0011) at week 14 versus ACR-Pedi-30 nonresponders.
  
  
  CONCLUSIONS
  Infliximab + MTX attenuated several inflammatory markers in patients with JIA; larger decreases in ICAM-1, MMP-3, and CRP levels were observed in ACR-Pedi-30 responders versus nonresponders.
  
  
  BACKGROUND
  NCT00036374.
authors.affiliation: IRCCS G, Gaslini and University of Genoa, Genoa, Italy. nicolaruperto@ospedale-gaslini.ge.it.
authors.forename: Sudha
authors.initials: S
authors.lastname: Visvanathan
authors.forename: Carrie
authors.initials: C
authors.lastname: Wagner
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Marini
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Lovell
authors.forename: Alberto
authors.initials: A
authors.lastname: Martini
authors.forename: Ross
authors.initials: R
authors.lastname: Petty
authors.forename: Ruben
authors.initials: R
authors.lastname: Cuttica
authors.forename: Patricia
authors.initials: P
authors.lastname: Woo
authors.forename: Graciela
authors.initials: G
authors.lastname: Espada
authors.forename: Marco
authors.initials: M
authors.lastname: Gattorno
authors.forename: Maria T
authors.initials: MT
authors.lastname: Apaz
authors.forename: Eileen
authors.initials: E
authors.lastname: Baildam
authors.forename: Anders
authors.initials: A
authors.lastname: Fasth
authors.forename: Valeria
authors.initials: V
authors.lastname: Gerloni
authors.forename: Pekka
authors.initials: P
authors.lastname: Lahdenne
authors.forename: Pierre
authors.initials: P
authors.lastname: Quartier
authors.forename: Rotraud
authors.initials: R
authors.lastname: Saurenmann
authors.forename: Suzanne
authors.initials: S
authors.lastname: Travers
authors.forename: Alan
authors.initials: A
authors.lastname: Mendelsohn
authors.forename: Stephen
authors.initials: S
authors.lastname: Xu
authors.forename: Edward H
authors.initials: EH
authors.lastname: Giannini
authors.forename: Nicolino
authors.initials: N
authors.lastname: Ruperto
references.citation: N Engl J Med. 2008 Aug 21;359(8):810-20
references.pmid: 18716298
references.citation: Lancet. 2007 Mar 3;369(9563):767-778
references.pmid: 17336654
references.citation: J Rheumatol. 2002 Feb;29(2):369-78
references.pmid: 11838858
references.citation: Clin Exp Rheumatol. 1992 Sep-Oct;10(5):493-8
references.pmid: 1458703
references.citation: Curr Opin Rheumatol. 1999 Sep;11(5):377-83
references.pmid: 10503658
references.citation: J Rheumatol. 2007 Jul;34(7):1465-74
references.pmid: 17552048
references.citation: J Rheumatol. 1990 Jun;17(6):827-30
references.pmid: 2388206
references.citation: Arthritis Rheum. 2004 Jul;50(7):2191-201
references.pmid: 15248217
references.citation: J Rheumatol. 2008 Mar;35(3):515-9
references.pmid: 18203309
references.citation: Scand J Rheumatol. 2007 May-Jun;36(3):189-93
references.pmid: 17657672
references.citation: J Rheumatol. 2002 Apr;29(4):826-31
references.pmid: 11950028
references.citation: Clin Exp Rheumatol. 2002 Mar-Apr;20(2):249-54
references.pmid: 12051408
references.citation: J Rheumatol. 1999 Oct;26(10):2244-8
references.pmid: 10529148
references.citation: Arthritis Rheum. 1996 Aug;39(8):1385-90
references.pmid: 8702448
references.citation: Arthritis Rheum. 1997 Jul;40(7):1202-9
references.pmid: 9214419
references.citation: Arthritis Rheum. 2007 Sep;56(9):3096-106
references.pmid: 17763439
references.citation: N Engl J Med. 2000 Mar 16;342(11):763-9
references.pmid: 10717011